Edgewise Therapeutics, Inc.
EWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710072
In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Edgewise Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 31 | 46 | +15 |
| Shares | 45.7M | 47.9M | +2.20M (+4.8%) |
| Value | $1.48B | $1.03B | −$449.0M (−30.4%) |
New holders (23)
Institutions that held Edgewise Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (8)
Institutions that held Edgewise Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 300,000 | $9.75M |
| Sphera Funds Management Ltd. | 100,000 | $3.25M |
| Goldman Sachs Group Inc | 65,263 | $2.12M |
| Millennium Management LLC | 60,077 | $1.95M |
| Caas Capital Management LP | 30,000 | $975.0K |
| Squarepoint Ops LLC | 20,185 | $656.0K |
| Landscape Capital Management, L.L.C. | 8,923 | $290.0K |
| Maven Securities LTD | 8,300 | $262.0K |